Loading…
Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes
Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain,...
Saved in:
Published in: | Blood 1998-09, Vol.92 (5), p.1565-1575 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713 |
---|---|
cites | cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713 |
container_end_page | 1575 |
container_issue | 5 |
container_start_page | 1565 |
container_title | Blood |
container_volume | 92 |
creator | WHITWAM, T HASKINS, M. E HENTHORN, P. S KRASZEWSKI, J. N KLEIMAN, S. E SEIDEL, N. E BODINE, D. M PUCK, J. M |
description | Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use. |
doi_str_mv | 10.1182/blood.v92.5.1565 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73867453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73867453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</originalsourceid><addsrcrecordid>eNo9kV2L1DAUhoMo67h6742QC_HKjvlo0tQ7WfyCgYVFvQ1pejqNJk1N2lnnf_iDzbizCyGBc573PeS8CL2kZEupYu86H2O_PbRsK7ZUSPEIbahgqiKEkcdoQwiRVd029Cl6lvNPQmjNmbhAF6Ukhao36O8NLCkeXDIeB5N-uWmP44CtmdwEuIvlKuUUb_F7vIvTvloghbd4dPux8nAAj-HPnCBnF6eTcFyDmbCbCuZhLXYVwwkszEtM2MYQCrY3IRhsR-NO5P0sfwzzGO1xgfwcPRmMz_Di_F6i758-frv6Uu2uP3-9-rCrLONqqXpLDfTSMENFN4DkSgkLgySmEXXHO-Cst6IdBhDQc8VtbantW1YOU9BQfone3PnOKf5eIS86uGzBezNBXLNuuJJNLXgByR1oU8w5waDn5MpejpoSfQpC_w9C_2iZFvoURJG8OnuvXYD-QXDefOm_PvdNtsYPyUzW5QeMcSnLJ_k__SaWAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73867453</pqid></control><display><type>article</type><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><source>ScienceDirect</source><creator>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</creator><creatorcontrib>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</creatorcontrib><description>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.v92.5.1565</identifier><identifier>PMID: 9716584</identifier><language>eng</language><publisher>Washington, DC: The Americain Society of Hematology</publisher><subject>AIDS/HIV ; Animals ; Biological and medical sciences ; Biotechnology ; Bone Marrow - metabolism ; Bone Marrow Transplantation ; Dogs ; Fundamental and applied biological sciences. Psychology ; Gene Expression ; Gene therapy ; Gene Transfer Techniques ; Genetic Markers ; Genetic Therapy ; Granulocyte Colony-Stimulating Factor - pharmacology ; Health. Pharmaceutical industry ; Humans ; Immunosuppression ; Industrial applications and implications. Economical aspects ; Lymphocytes - metabolism ; Receptors, Interleukin-2 - genetics ; Retroviridae - genetics ; Severe Combined Immunodeficiency - genetics ; Severe Combined Immunodeficiency - therapy ; Stem Cell Factor - pharmacology ; X Chromosome</subject><ispartof>Blood, 1998-09, Vol.92 (5), p.1565-1575</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</citedby><cites>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2366238$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9716584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WHITWAM, T</creatorcontrib><creatorcontrib>HASKINS, M. E</creatorcontrib><creatorcontrib>HENTHORN, P. S</creatorcontrib><creatorcontrib>KRASZEWSKI, J. N</creatorcontrib><creatorcontrib>KLEIMAN, S. E</creatorcontrib><creatorcontrib>SEIDEL, N. E</creatorcontrib><creatorcontrib>BODINE, D. M</creatorcontrib><creatorcontrib>PUCK, J. M</creatorcontrib><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><title>Blood</title><addtitle>Blood</addtitle><description>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</description><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biotechnology</subject><subject>Bone Marrow - metabolism</subject><subject>Bone Marrow Transplantation</subject><subject>Dogs</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression</subject><subject>Gene therapy</subject><subject>Gene Transfer Techniques</subject><subject>Genetic Markers</subject><subject>Genetic Therapy</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Health. Pharmaceutical industry</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Industrial applications and implications. Economical aspects</subject><subject>Lymphocytes - metabolism</subject><subject>Receptors, Interleukin-2 - genetics</subject><subject>Retroviridae - genetics</subject><subject>Severe Combined Immunodeficiency - genetics</subject><subject>Severe Combined Immunodeficiency - therapy</subject><subject>Stem Cell Factor - pharmacology</subject><subject>X Chromosome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNo9kV2L1DAUhoMo67h6742QC_HKjvlo0tQ7WfyCgYVFvQ1pejqNJk1N2lnnf_iDzbizCyGBc573PeS8CL2kZEupYu86H2O_PbRsK7ZUSPEIbahgqiKEkcdoQwiRVd029Cl6lvNPQmjNmbhAF6Ukhao36O8NLCkeXDIeB5N-uWmP44CtmdwEuIvlKuUUb_F7vIvTvloghbd4dPux8nAAj-HPnCBnF6eTcFyDmbCbCuZhLXYVwwkszEtM2MYQCrY3IRhsR-NO5P0sfwzzGO1xgfwcPRmMz_Di_F6i758-frv6Uu2uP3-9-rCrLONqqXpLDfTSMENFN4DkSgkLgySmEXXHO-Cst6IdBhDQc8VtbantW1YOU9BQfone3PnOKf5eIS86uGzBezNBXLNuuJJNLXgByR1oU8w5waDn5MpejpoSfQpC_w9C_2iZFvoURJG8OnuvXYD-QXDefOm_PvdNtsYPyUzW5QeMcSnLJ_k__SaWAQ</recordid><startdate>19980901</startdate><enddate>19980901</enddate><creator>WHITWAM, T</creator><creator>HASKINS, M. E</creator><creator>HENTHORN, P. S</creator><creator>KRASZEWSKI, J. N</creator><creator>KLEIMAN, S. E</creator><creator>SEIDEL, N. E</creator><creator>BODINE, D. M</creator><creator>PUCK, J. M</creator><general>The Americain Society of Hematology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980901</creationdate><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><author>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biotechnology</topic><topic>Bone Marrow - metabolism</topic><topic>Bone Marrow Transplantation</topic><topic>Dogs</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression</topic><topic>Gene therapy</topic><topic>Gene Transfer Techniques</topic><topic>Genetic Markers</topic><topic>Genetic Therapy</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Health. Pharmaceutical industry</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Industrial applications and implications. Economical aspects</topic><topic>Lymphocytes - metabolism</topic><topic>Receptors, Interleukin-2 - genetics</topic><topic>Retroviridae - genetics</topic><topic>Severe Combined Immunodeficiency - genetics</topic><topic>Severe Combined Immunodeficiency - therapy</topic><topic>Stem Cell Factor - pharmacology</topic><topic>X Chromosome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WHITWAM, T</creatorcontrib><creatorcontrib>HASKINS, M. E</creatorcontrib><creatorcontrib>HENTHORN, P. S</creatorcontrib><creatorcontrib>KRASZEWSKI, J. N</creatorcontrib><creatorcontrib>KLEIMAN, S. E</creatorcontrib><creatorcontrib>SEIDEL, N. E</creatorcontrib><creatorcontrib>BODINE, D. M</creatorcontrib><creatorcontrib>PUCK, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WHITWAM, T</au><au>HASKINS, M. E</au><au>HENTHORN, P. S</au><au>KRASZEWSKI, J. N</au><au>KLEIMAN, S. E</au><au>SEIDEL, N. E</au><au>BODINE, D. M</au><au>PUCK, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1998-09-01</date><risdate>1998</risdate><volume>92</volume><issue>5</issue><spage>1565</spage><epage>1575</epage><pages>1565-1575</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</abstract><cop>Washington, DC</cop><pub>The Americain Society of Hematology</pub><pmid>9716584</pmid><doi>10.1182/blood.v92.5.1565</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 1998-09, Vol.92 (5), p.1565-1575 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_73867453 |
source | ScienceDirect |
subjects | AIDS/HIV Animals Biological and medical sciences Biotechnology Bone Marrow - metabolism Bone Marrow Transplantation Dogs Fundamental and applied biological sciences. Psychology Gene Expression Gene therapy Gene Transfer Techniques Genetic Markers Genetic Therapy Granulocyte Colony-Stimulating Factor - pharmacology Health. Pharmaceutical industry Humans Immunosuppression Industrial applications and implications. Economical aspects Lymphocytes - metabolism Receptors, Interleukin-2 - genetics Retroviridae - genetics Severe Combined Immunodeficiency - genetics Severe Combined Immunodeficiency - therapy Stem Cell Factor - pharmacology X Chromosome |
title | Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A15%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retroviral%20marking%20of%20canine%20bone%20marrow%20:%20Long-term,%20high-level%20expression%20of%20human%20interleukin-2%20receptor%20common%20gamma%20chain%20in%20canine%20lymphocytes&rft.jtitle=Blood&rft.au=WHITWAM,%20T&rft.date=1998-09-01&rft.volume=92&rft.issue=5&rft.spage=1565&rft.epage=1575&rft.pages=1565-1575&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.v92.5.1565&rft_dat=%3Cproquest_cross%3E73867453%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73867453&rft_id=info:pmid/9716584&rfr_iscdi=true |